New drug combo aims to shrink tough tumors
NCT ID NCT03697304
Summary
This study tested a new immunotherapy drug called ezabenlimab, given in combination with other cancer medicines, for adults with advanced cancers that had spread. The goal was to see if these combinations could shrink tumors and control the disease in patients who had already tried at least one other treatment. Doctors monitored tumor size and patient health to determine if the treatments were effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN, United Kingdom
-
Cross Cancer Institute (University of Alberta)
Edmonton, Alberta, T6G 1Z2, Canada
-
Florida Cancer Specialists - East
West Palm Beach, Florida, 33401, United States
-
Florida Cancer Specialists-Fort Myers-52980
Fort Myers, Florida, 33901, United States
-
Florida Cancer Specialists-Saint Petersburg-52979
St. Petersburg, Florida, 33705, United States
-
Florida Cancer Specialists-Sarasota-61670
Tallahassee, Florida, 32308, United States
-
Guy's Hospital
London, SE1 9RT, United Kingdom
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Medical College Of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Norton Cancer Institute
Louisville, Kentucky, 40202, United States
-
Oklahoma University School of Community Medicine
Oklahoma City, Oklahoma, 73104, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 1Z6, Canada
-
Sarah Cannon Research Institute, London
London, W1G 6AD, United Kingdom
-
Tennessee Oncology
Chattanooga, Tennessee, 37404, United States
-
Tennessee Oncology, PLLC-Nashville-52568
Nashville, Tennessee, 37203, United States
-
University College Hospital
London, NW1 2BU, United Kingdom
-
University of California San Diego
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.